These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26428295)

  • 1. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.
    Mancini M; Yarden Y
    Semin Cell Dev Biol; 2016 Feb; 50():164-76. PubMed ID: 26428295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance.
    Murray BW; Miller N
    Mol Cancer Ther; 2015 Sep; 14(9):1975-84. PubMed ID: 26264276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.
    Faes S; Demartines N; Dormond O
    Oxid Med Cell Longev; 2017; 2017():1726078. PubMed ID: 28280521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation.
    Trusolino L; Bertotti A
    Cancer Discov; 2012 Oct; 2(10):876-80. PubMed ID: 23071031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.
    Angus SP; Zawistowski JS; Johnson GL
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():209-229. PubMed ID: 28934561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feedback regulation in cell signalling: Lessons for cancer therapeutics.
    Nguyen LK; Kholodenko BN
    Semin Cell Dev Biol; 2016 Feb; 50():85-94. PubMed ID: 26481970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.
    Das Thakur M; Stuart DD
    Clin Cancer Res; 2014 Mar; 20(5):1074-80. PubMed ID: 24352648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
    Bagrodia S; Smeal T; Abraham RT
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.
    Buschbeck M
    Drugs R D; 2006; 7(2):73-86. PubMed ID: 16542054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK in cancer and cancer therapy.
    Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
    Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
    Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
    Bixby D; Talpaz M
    Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
    Whittaker S; Kirk R; Hayward R; Zambon A; Viros A; Cantarino N; Affolter A; Nourry A; Niculescu-Duvaz D; Springer C; Marais R
    Sci Transl Med; 2010 Jun; 2(35):35ra41. PubMed ID: 20538618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
    Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
    Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies.
    Lovly CM; Shaw AT
    Clin Cancer Res; 2014 May; 20(9):2249-56. PubMed ID: 24789032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.